You just missed a question on furosemide and it feels annoying because “loop diuretic” seems straightforward—until the vignette sneaks in calcium, ototoxicity, metabolic alkalosis, and kidney stones. This is exactly why Q-bank items love loops: one drug lights up multiple physiologic pathways, and every distractor is a mini-lesson. Let’s break one down like you’re reviewing with a friend who already took Step.
Clinical Vignette (Q-bank style)
A 67-year-old man with acute decompensated heart failure is treated with IV furosemide for pulmonary edema. Over the next 24 hours, his urine output increases significantly. On morning labs, he is noted to have:
- Na⁺: 140 mEq/L
- K⁺: 3.0 mEq/L
- Cl⁻: 92 mEq/L
- HCO₃⁻: 34 mEq/L
- pH: 7.50
- New complaint: ringing in his ears
Which of the following best explains his lab findings?
A. Inhibition of Na⁺/Cl⁻ cotransporter in the distal convoluted tubule
B. Inhibition of Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb
C. Blockade of aldosterone receptor in the collecting duct
D. Inhibition of carbonic anhydrase in the proximal tubule
E. Inhibition of ADH (V2) receptor in the collecting duct
The Correct Answer: B. Inhibition of Na⁺-K⁺-2Cl⁻ (NKCC2) in the Thick Ascending Limb
Loop diuretics (furosemide, bumetanide, torsemide, ethacrynic acid) inhibit NKCC2 in the thick ascending limb (TAL). That single move triggers the classic Step-worthy downstream effects:
Why the patient has hypokalemic metabolic alkalosis
Loop diuretics cause:
- Salt and water loss → volume contraction
- RAAS activation (↑ renin, ↑ aldosterone)
- More Na⁺ delivery to the collecting duct → principal cells reabsorb Na⁺ in exchange for secreting K⁺
- Aldosterone also increases H⁺ secretion by α-intercalated cells
Result: hypokalemia + metabolic alkalosis.
Board phrase: “Contraction alkalosis” + K⁺ wasting.
Why tinnitus shows up
Loop diuretics can cause ototoxicity, especially:
- At high doses
- With IV administration
- When combined with other ototoxins (e.g., aminoglycosides)
Mechanistically, NKCC transporters are also present in the inner ear; disrupting ionic gradients can impair hearing.
Why loops affect calcium and stones
In the TAL, NKCC2 normally helps create a lumen-positive potential (via ROMK-mediated K⁺ back-leak), which drives paracellular reabsorption of Ca²⁺ and Mg²⁺. Blocking NKCC2 → less lumen-positive potential → less Ca²⁺/Mg²⁺ reabsorption → increased urinary calcium.
High-yield line:
- Loops = “Lose Ca²⁺” → hypercalciuria → increased risk of calcium stones
High-Yield Snapshot: Loop Diuretics (Furosemide)
| Feature | High-yield detail |
|---|---|
| Site of action | Thick ascending limb (TAL) |
| Transporter blocked | Na⁺-K⁺-2Cl⁻ (NKCC2) |
| Effect on urine | ↑ Na⁺, ↑ water, ↑ K⁺, ↑ H⁺, ↑ Ca²⁺, ↑ Mg²⁺ excretion |
| Acid-base | Metabolic alkalosis (contraction + aldosterone) |
| Key adverse effects | Ototoxicity, hypokalemia, dehydration, sulfa allergy (except ethacrynic acid), hyperuricemia |
| Stone tie-in | Hypercalciuria → Ca²⁺ stones |
Mnemonic you actually use:
- Loops lose Ca²⁺
- Thiazides save Ca²⁺
Now Kill the Distractors (Why Each Wrong Choice Is Tempting)
A. Na⁺/Cl⁻ cotransporter inhibition in the DCT (Thiazides) — Wrong
This is thiazides (e.g., hydrochlorothiazide, chlorthalidone, indapamide).
Why it’s tempting: thiazides also cause hypokalemic metabolic alkalosis.
How to separate from loops fast:
- Thiazides increase Ca²⁺ reabsorption → hypocalciuria
- Used to prevent calcium stones (idiopathic hypercalciuria)
- Classic metabolic effect: can cause hyperglycemia, hyperlipidemia (Step-style associations)
If the vignette emphasizes tinnitus/ototoxicity or hypercalciuria, think loop, not thiazide.
C. Aldosterone receptor blockade (Spironolactone/eplerenone) — Wrong
This is potassium-sparing, acting in the collecting duct.
Expected effects:
- Hyperkalemia
- Metabolic acidosis (type 4 RTA physiology vibes)
So if you see low K⁺ and alkalosis, aldosterone blockade doesn’t fit.
Extra Step hooks:
- Spironolactone: gynecomastia, impotence (antiandrogen)
- Eplerenone: fewer endocrine side effects
D. Carbonic anhydrase inhibition in the proximal tubule (Acetazolamide) — Wrong
Acetazolamide blocks carbonic anhydrase → decreased bicarbonate reabsorption.
Expected acid-base:
- Metabolic acidosis (loss of HCO₃⁻ in urine)
Other high-yield associations:
- Used for altitude sickness, glaucoma, idiopathic intracranial hypertension
- Can cause calcium phosphate stones due to alkaline urine (this is a classic distractor!)
How to not fall for it:
- Acetazolamide → alkaline urine + metabolic acidosis
- Loop diuretic → metabolic alkalosis
E. ADH (V2) receptor inhibition in the collecting duct (Conivaptan/tolvaptan or nephrogenic DI) — Wrong
Blocking ADH (or nephrogenic diabetes insipidus) causes:
- Dilute urine
- Hypernatremia risk
- No characteristic hypokalemic metabolic alkalosis pattern
If the stem emphasizes euvolemic hyponatremia (SIADH) → vaptans.
If it emphasizes hypokalemic metabolic alkalosis + ototoxicity → loop.
The Renal Stones Tie-In You’re Expected to Know
USMLE loves pairing diuretics with stones:
Loop diuretics → calcium stones
- Increase urinary Ca²⁺ (hypercalciuria)
- Risk rises with volume depletion (more concentrated urine)
Thiazides → prevent calcium stones
- Decrease urinary Ca²⁺ (hypocalciuria)
- Especially useful in idiopathic hypercalciuria
Quick comparison table:
| Drug class | Urinary Ca²⁺ | Stone implication |
|---|---|---|
| Loop diuretics | ↑ | Promote Ca²⁺ stones |
| Thiazides | ↓ | Prevent Ca²⁺ stones |
| Acetazolamide | Variable; alkalinizes urine | Can promote Ca phosphate stones |
Rapid-Fire USMLE Pearls (Loops)
- Furosemide is a sulfonamide → allergy risk (except ethacrynic acid)
- Hyperuricemia → gout flares (volume contraction increases urate reabsorption)
- Ototoxicity is more likely with ethacrynic acid and with aminoglycosides
- TAL is the diluting segment → loops impair urine dilution and disrupt medullary gradient
How to Answer These in 10 Seconds on Test Day
Look for a loop pattern:
- Hypokalemia + metabolic alkalosis
- Ototoxicity
- Hypercalciuria (± stones)
- Big diuresis in pulmonary edema/heart failure
If those show up, pick:
- NKCC2 inhibition in the thick ascending limb.